Neoantigens in cancer immunotherapy
- PMID: 25838375
- DOI: 10.1126/science.aaa4971
Neoantigens in cancer immunotherapy
Abstract
The clinical relevance of T cells in the control of a diverse set of human cancers is now beyond doubt. However, the nature of the antigens that allow the immune system to distinguish cancer cells from noncancer cells has long remained obscure. Recent technological innovations have made it possible to dissect the immune response to patient-specific neoantigens that arise as a consequence of tumor-specific mutations, and emerging data suggest that recognition of such neoantigens is a major factor in the activity of clinical immunotherapies. These observations indicate that neoantigen load may form a biomarker in cancer immunotherapy and provide an incentive for the development of novel therapeutic approaches that selectively enhance T cell reactivity against this class of antigens.
Copyright © 2015, American Association for the Advancement of Science.
Similar articles
-
An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth.Cancer Discov. 2021 Mar;11(3):696-713. doi: 10.1158/2159-8290.CD-20-0377. Epub 2021 Jan 27. Cancer Discov. 2021. PMID: 33504579
-
Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.J Clin Invest. 2019 Mar 5;129(5):2056-2070. doi: 10.1172/JCI99538. Print 2019 May 1. J Clin Invest. 2019. PMID: 30835255 Free PMC article.
-
Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.Eur J Cancer. 2017 Oct;84:290-303. doi: 10.1016/j.ejca.2017.07.026. Epub 2017 Aug 29. Eur J Cancer. 2017. PMID: 28846956 Review.
-
Neoantigen vaccine: an emerging tumor immunotherapy.Mol Cancer. 2019 Aug 23;18(1):128. doi: 10.1186/s12943-019-1055-6. Mol Cancer. 2019. PMID: 31443694 Free PMC article. Review.
-
Advances in personalized neoantigen vaccines for cancer immunotherapy.Biosci Trends. 2020 Nov 4;14(5):349-353. doi: 10.5582/bst.2020.03267. Epub 2020 Sep 10. Biosci Trends. 2020. PMID: 32908077 Review.
Cited by
-
A T cell receptor specific for an HLA-A*03:01-restricted epitope in the endogenous retrovirus ERV-K-Env exhibits limited recognition of its cognate epitope.Mob DNA. 2024 Oct 9;15(1):19. doi: 10.1186/s13100-024-00333-w. Mob DNA. 2024. PMID: 39385229 Free PMC article.
-
Super multiple primary lung cancers harbor high-frequency BRAF and low-frequency EGFR mutations in the MAPK pathway.NPJ Precis Oncol. 2024 Oct 9;8(1):229. doi: 10.1038/s41698-024-00726-3. NPJ Precis Oncol. 2024. PMID: 39384982 Free PMC article.
-
Actin-related protein 2/3 complex subunit 1B promotes ovarian cancer progression by regulating the AKT/PI3K/mTOR signaling pathway.J Transl Int Med. 2024 Oct 1;12(4):406-423. doi: 10.2478/jtim-2024-0025. eCollection 2024 Sep. J Transl Int Med. 2024. PMID: 39360160 Free PMC article.
-
Tumor immunogenicity regulates host immune responses, and conventional dendritic cell type 2 uptakes the majority of tumor antigens in an orthotopic lung cancer model.Cancer Immunol Immunother. 2024 Oct 3;73(12):237. doi: 10.1007/s00262-024-03828-w. Cancer Immunol Immunother. 2024. PMID: 39358651 Free PMC article.
-
Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab.Nat Med. 2024 Sep 30. doi: 10.1038/s41591-024-03240-y. Online ahead of print. Nat Med. 2024. PMID: 39349627
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
